Partner and Localizer of BRAC2
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| PALB2-101AP | PALB2 antibodies | Rabbit | AP | r, m, h | 100.0 ug | 150-500 ul |
$245.00
|
| FITC-PALB2 | FITC-conjugated antibodies | Rabbit | FITC-AP | r, m, h | 100.0 ug | 150-500 ul |
$350.00
|
| P-PALB2 | Antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| PC-PALB2 | WB positive control for PALB2 | n/a | Protein in ready-to-use buffer | n/a | 0.0 ug | 150 ul |
$185.00
|
The dominantly inherited two genes, BRCA1 and BRCA2 that contribute approximately 3-5% of breast cancer, account for approximately 85% of families with four or more cases of breast and ovarian cancer (1). Soon after these genes were discovered, it became apparent that specific founder mutations in these genes were present in different ethnic groups (2), at least 5 founder mutations were discovered that account for 75-85% of all BRCA1/2 mutations in specific ethnic group. However, for approximately one half of strongly hereditary breast cancer families, no BRCA1/2 mutation has been identified and other genes are believed to be important. Several known hereditary genes (BRCA1, BRCA2, CHEK2, TP53, ATM, FANCJ/BRIP1) are known to work in concert in DNA repair pathway which raises the possibility of other genes that might be involved in this pathway and are predispose to breast and other types of cancer (3). Recently identified gene Partner and localizer of BRCA2 (PALB2) is associated with breast cancer susceptibility in the Finland and other European countries. Finland population has shown mutations in PALB2 but these mutations are rare cause of breast cancer incidence in that country (4).
PALB2 is identified to play an important role in facilitating the function of BRCA2; nearly 50% of BRCA2 is associated with PALB2 and more than 50% of PALB2 forms a complex with BRCA2. Association of BRCA2 with PALB2 appears to be essential for BRCA2 anchorage to nuclear structures and for its function in homologous recombination and double-strand break repair (5). The PALB2 may also act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effect of proteosome-mediated degradation. Recent studies suggest that PALB2 is another form of FA gene also known ad FANCN, and FANCMN disease resembles FA arising from biallelic BRCA2 mutations in the affected children that are prone to embryonic tumors and early bone marrow failures. These patients exhibit increased chromosomal breakage after interstrand cross-linking agent exposure, exhibit growth retardation and various congenital malformations (6). The mutations in BRCA2 gene in prostate cancer have been associated with increased prostate cancer risk and account for around 2% of young onset of prostate cancer cases. Interactions of PALB2 with BRCA2 and its role in DNA double stranded break repair suggest a role of PALB2 in prostate cancer. Two previously unreported variants of PALB2, K18R and V925L were identified, neither of which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic in prostate cancer (6). PALB2 (1186 aa) is highly conserved protein expressed in at least 2 variant isoforms in human and mouse/rats is localized on the short arm of chromosome 16p12.1 at position 23,521,983-23,560,127bp.
The PALB2-selective antibodies were generated against an epitope that is common in human and rat/mouse PALB2 protein near the C-terminal end of the protein. The PALB2-selective antibodies are affinity purified against immobilized antigen based affinity chromatography which yielded epitope-specific antibodies. The PALB2 antibodies label an approximately 135kDa protein in Western blot using PC-PALB2 sample. Anti-PALB2-selective antibodies are also available in FITC-conjugated form for confocal, Western blotting and immunocytochemical analyses. FabGennix Inc. will also conjugate antibodies with fluorescent probes upon request at a nominal extra charge. Limited quantities of antigenic blocking peptide and western blot positive control are also available (inquire before ordering). FabGennix Inc. also provides antibodies to other cancer targets, for a complete listing please visit www.FabGennix.com.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search